The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana ...

On Dec. 19, Mesoblast announced the U.S. Food and Drug Administration (FDA) approved Ryoncil. Ryoncil is the first FDA ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...